ImmunoScape, Based in Singapore, Leads Development of Advanced Cell Therapy for Solid Tumors; Reveals Major Licensing Agreement and New Board and SAB Appointments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy CUE?
Source: Newsfilter
Innovative Cancer Immunotherapy: ImmunoScape has partnered with Cue Biopharma to develop a new "Seed-and-Boost" immunotherapy approach that enhances T cell expansion and targets solid tumors, aiming to improve patient outcomes in various cancers.
Targeted Clinical Programs: The initial focus of ImmunoScape's clinical program is on the WT1 antigen, which is prevalent in several difficult-to-treat solid tumors, with plans to begin clinical trials by 2027 based on promising preclinical data.
Leadership Enhancements: ImmunoScape has strengthened its leadership team with key appointments, including experts from Cue Biopharma and other biotech firms, to drive innovation in cancer immunotherapy.
Support and Collaboration: The company acknowledges the support from local and global partners, including A*STAR and various investors, which has been crucial for its pioneering work in developing next-generation cancer treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CUE
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
Cue Biopharma Prices $10 Million Public Offering of Common Stock
- Offering Overview: Cue Biopharma has announced a public offering of 35,714,286 shares at a price of $0.28 per share, expected to raise approximately $10 million, enhancing liquidity to support ongoing R&D efforts.
- Warrant Details: Each common stock warrant has an exercise price of $0.30, is immediately exercisable, and expires five years from issuance, aimed at attracting investors and increasing market participation.
- Underwriter Arrangement: H.C. Wainwright & Co. is acting as the sole book-running manager for the offering, with Newbridge Securities Corporation as co-manager, ensuring professionalism and efficiency in the issuance process.
- Registration Statement Background: The offering is made under an effective shelf registration statement filed in May 2023, reflecting the company's commitment to compliance and transparency, which may enhance investor confidence.
See More
Cue Biopharma Launches $10M Underwritten Public Offering; Stock Declines
Public Offering Details: Cue Biopharma has announced an underwritten public offering of 35.71 million shares at a combined price of $0.28 per unit, expected to generate approximately $10 million in gross proceeds.
Warrants Information: The offering includes warrants covering up to 17.86 million shares, with an exercise price of $0.30 per share, exercisable immediately and expiring five years from issuance.
Closing Date: The offering is anticipated to close on or about December 22, 2025, with underwriters having a 30-day option to purchase additional shares and warrants.
Market Reaction: Following the announcement, Cue Biopharma's shares fell by 22.7% in premarket trading on Friday.
See More
Cue Biopharma Launches Underwritten Public Offering with 15% Additional Shares Option
- Public Offering Initiation: Cue Biopharma has announced the commencement of an underwritten public offering of common stock and accompanying warrants, aiming to strengthen its capital base to support ongoing R&D despite the exact size being uncertain.
- Underwriter Selection: H.C. Wainwright & Co. is acting as the sole book-running manager for the offering, with Newbridge Securities Corporation as co-manager, indicating market recognition of the company's financing needs.
- Market Condition Impact: The completion of the offering will be subject to market and other conditions, as Cue Biopharma must navigate its limited operating history and cash position to ensure successful financing.
- Future Outlook: The offering aligns with Cue Biopharma's strategy to develop biologics targeting autoimmune diseases, and if successful, it will significantly contribute to the company's long-term growth in the biopharmaceutical sector.
See More
Cue Biopharma Launches Underwritten Public Offering with 15% Additional Shares Option
- Public Offering Initiation: Cue Biopharma has announced the commencement of an underwritten public offering of common stock and warrants, aimed at funding its biopharmaceutical research and development, although market conditions remain uncertain.
- Additional Shares Option: The company will grant underwriters the option to purchase up to an additional 15% of the shares within 30 days, enhancing its financing flexibility and potentially providing more funding for future R&D efforts.
- Effective Registration Statement: The offering is conducted under an effective registration statement filed in May 2023, ensuring compliance and providing transparency for investors regarding the offering details.
- Market Risk Advisory: Cue Biopharma cautions investors that the completion and terms of the offering are subject to market conditions, highlighting the potential uncertainties the company faces in financing and operations.
See More
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
Cue Biopharma Prices $10 Million Public Offering of Common Stock
- Offering Overview: Cue Biopharma has announced a public offering of 35,714,286 shares at a price of $0.28 per share, expected to raise approximately $10 million, enhancing liquidity to support ongoing R&D efforts.
- Warrant Details: Each common stock warrant has an exercise price of $0.30, is immediately exercisable, and expires five years from issuance, aimed at attracting investors and increasing market participation.
- Underwriter Arrangement: H.C. Wainwright & Co. is acting as the sole book-running manager for the offering, with Newbridge Securities Corporation as co-manager, ensuring professionalism and efficiency in the issuance process.
- Registration Statement Background: The offering is made under an effective shelf registration statement filed in May 2023, reflecting the company's commitment to compliance and transparency, which may enhance investor confidence.
See More
Cue Biopharma Launches $10M Underwritten Public Offering; Stock Declines
Public Offering Details: Cue Biopharma has announced an underwritten public offering of 35.71 million shares at a combined price of $0.28 per unit, expected to generate approximately $10 million in gross proceeds.
Warrants Information: The offering includes warrants covering up to 17.86 million shares, with an exercise price of $0.30 per share, exercisable immediately and expiring five years from issuance.
Closing Date: The offering is anticipated to close on or about December 22, 2025, with underwriters having a 30-day option to purchase additional shares and warrants.
Market Reaction: Following the announcement, Cue Biopharma's shares fell by 22.7% in premarket trading on Friday.
See More
Cue Biopharma Launches Underwritten Public Offering with 15% Additional Shares Option
- Public Offering Initiation: Cue Biopharma has announced the commencement of an underwritten public offering of common stock and accompanying warrants, aiming to strengthen its capital base to support ongoing R&D despite the exact size being uncertain.
- Underwriter Selection: H.C. Wainwright & Co. is acting as the sole book-running manager for the offering, with Newbridge Securities Corporation as co-manager, indicating market recognition of the company's financing needs.
- Market Condition Impact: The completion of the offering will be subject to market and other conditions, as Cue Biopharma must navigate its limited operating history and cash position to ensure successful financing.
- Future Outlook: The offering aligns with Cue Biopharma's strategy to develop biologics targeting autoimmune diseases, and if successful, it will significantly contribute to the company's long-term growth in the biopharmaceutical sector.
See More
Cue Biopharma Launches Underwritten Public Offering with 15% Additional Shares Option
- Public Offering Initiation: Cue Biopharma has announced the commencement of an underwritten public offering of common stock and warrants, aimed at funding its biopharmaceutical research and development, although market conditions remain uncertain.
- Additional Shares Option: The company will grant underwriters the option to purchase up to an additional 15% of the shares within 30 days, enhancing its financing flexibility and potentially providing more funding for future R&D efforts.
- Effective Registration Statement: The offering is conducted under an effective registration statement filed in May 2023, ensuring compliance and providing transparency for investors regarding the offering details.
- Market Risk Advisory: Cue Biopharma cautions investors that the completion and terms of the offering are subject to market conditions, highlighting the potential uncertainties the company faces in financing and operations.
See More
